>
Mayne Pharma logo

MYX - Mayne Pharma Share Price

A$0.46 0.0  1.1%

Last Trade - 7:10am

Sector
Healthcare
Size
Mid Cap
Market Cap £424.4m
Enterprise Value £547.3m
Revenue £244.2m
Position in Universe 339th / 1899
Bullish
Bearish
Unlock MYX Revenue
Momentum
Relative Strength (%)
1m +29.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -4.61%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
141.4 267.3 572.6 530.4 526.2 457.8 425 497 +26.5%
-49.4 +232.8 +13.4 -13.7 +700
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, MaynePharma Group Ltd revenues decreased 8% to A$209.4M. Netloss before extraordinary items increased from A$16.6M toA$181.8M. Revenues reflect Generic Products segmentdecrease of 13% to A$108.8M, Speciality Brands segmentdecrease of 10% to A$40.2M, United States segment decreaseof 10% to A$187.5M, Korea segment decrease of 32% toA$1.3M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

MYX Revenue Unlock MYX Revenue

Net Income

MYX Net Income Unlock MYX Revenue

Normalised EPS

MYX Normalised EPS Unlock MYX Revenue

PE Ratio Range

MYX PE Ratio Range Unlock MYX Revenue

Dividend Yield Range

MYX Dividend Yield Range Unlock MYX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MYX EPS Forecasts Unlock MYX Revenue
Profile Summary

Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated August 18, 2005
Public Since June 29, 2007
No. of Shareholders: 17,484
No. of Employees: 850
Sector Healthcare
Industry Pharmaceuticals
Index S&P/ASX All Ordinaries , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 1,679,068,131
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MYX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MYX
Upcoming Events for MYX
Thursday 26th August, 2021
Full Year 2021 Mayne Pharma Group Ltd Earnings Release
Frequently Asked Questions for Mayne Pharma
What is the Mayne Pharma share price?

As of 7:10am, shares in Mayne Pharma are trading at A$0.46, giving the company a market capitalisation of £424.4m. This share price information is delayed by 15 minutes.

How has the Mayne Pharma share price performed this year?

Shares in Mayne Pharma are currently trading at A$0.46 and the price has moved by 42.19% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Mayne Pharma price has moved by 8.24% over the past year.

What are the analyst and broker recommendations for Mayne Pharma?

Of the analysts with advisory recommendations for Mayne Pharma, there are there are currently 2 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Mayne Pharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Mayne Pharma next release its financial results?

Mayne Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Mayne Pharma dividend yield?

Mayne Pharma does not currently pay a dividend.

Does Mayne Pharma pay a dividend?

Mayne Pharma does not currently pay a dividend.

When does Mayne Pharma next pay dividends?

Mayne Pharma does not currently pay a dividend.

How do I buy Mayne Pharma shares?

To buy shares in Mayne Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Mayne Pharma?

Shares in Mayne Pharma are currently trading at A$0.46, giving the company a market capitalisation of £424.4m.

Where are Mayne Pharma shares listed? Where are Mayne Pharma shares listed?

Here are the trading details for Mayne Pharma:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: MYX
What kind of share is Mayne Pharma?

Based on an overall assessment of its quality, value and momentum, Mayne Pharma is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Mayne Pharma share price forecast 2021?

Shares in Mayne Pharma are currently priced at A$0.46. At that level they are trading at 16.26% premium to the analyst consensus target price of 0.00.

Analysts covering Mayne Pharma currently have a consensus Earnings Per Share (EPS) forecast of 0.001 for the next financial year.

How can I tell whether the Mayne Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mayne Pharma. Over the past six months, the relative strength of its shares against the market has been 20.92%. At the current price of A$0.46, shares in Mayne Pharma are trading at 29.16% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Mayne Pharma PE Ratio?

The Mayne Pharma PE ratio based on its reported earnings over the past 12 months is 22.17. The shares are currently trading at A$0.46.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Mayne Pharma?

Mayne Pharma's management team is headed by:

Bruce Mathieson - NID
Roger Corbett - NEC
Scott Richards - CEO
Peter Paltoglou - CFO
Nancy Dolan - NID
Frank Condella - NID
Patrick Blake - NID
Laura Loftus - SEC
Who are the major shareholders of Mayne Pharma?

Here are the top five shareholders of Mayne Pharma based on the size of their shareholding:

Investors Mutual Limited Investment Advisor
Percentage owned: 8.7% (146.0m shares)
Mathieson (Bruce Lawrence) Individual Investor
Percentage owned: 6.29% (105.6m shares)
Lazard Asset Management Pacific Company Investment Advisor
Percentage owned: 6.19% (104.0m shares)
Estetra SPRL Corporation
Percentage owned: 4.95% (83.1m shares)
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund
Percentage owned: 2.46% (41.4m shares)
Similar to MYX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.